Table 1.
Vaccine candidates in Phase III trials as of 30 January 2021.
| Manufacturer | Vaccine Candidates | Platform | Identifier | Location of Phase III Trials |
|---|---|---|---|---|
| Sinovac Biotech | CoronaVac | Inactivated virus | NCT04456595 | Brazil |
| NCT04582344 | Turkey | |||
| NCT04508075 | Indonesia | |||
| NCT04617483 | China | |||
| NCT04651790 | Chile | |||
| Beijing Institute of Biological Products/Sinopharm | BBIBP-CorV | Inactivated virus (Vero cell) | NCT04560881 | Argentina |
| NCT04510207 | United Arab Emirates, Bahrain, Egypt, Jordan | |||
| Wuhan Institute of Biological Products/Sinopharm | N/A | Inactivated virus (Vero cell) | ChiCTR2000039000 | Morocco |
| ChiCTR2000034780 | Bahrain, Egypt, United Arab Emirates | |||
| Institute of Medical Biology/Chinese Academy of Medical Sciences | N/A | Inactivated virus (Vero cell) | NCT04659239 | Brazil, Malaysia |
| Research Institute for Biological Safety Problems, Rep of Kazakhstan | QazCovid-in®-vaccine | Inactivated virus | NCT04691908 | Kazakhstan |
| Bharat Biotech International Limited | Covaxin (BBV152B) | Inactivated virus | NCT04641481 | India |
| CTRI/2020/11/028976 | India | |||
| Novavax | NVX-CoV2373 | Protein subunit (wild-type SARS-CoV-2 spike glycoprotein) |
NCT04611802 | United States of America |
| NCT04583995 | United Kingdom | |||
| EudraCT 2020-004123-16 | United Kingdom | |||
| BioNTech/Pfizer/Fosun Pharma | Comirnaty (BNT162b2) | mRNA (nucleoside-modified RNA (modRNA) encoding the SARS-CoV-2 full-length spike, with two proline mutations to lock it in the prefusion conformation) | NCT04368728 | United States of America, Argentina, Brazil, Germany, South Africa, Turkey |
| NCT04713553 | (Not recruiting yet) | |||
| Moderna/NIAID | mRNA-1273 | mRNA (encodes SARS-CoV-2 prefusion-stabilized full-length spike protein) |
NCT04649151 NCT04470427 |
United States of America |
| CureVac AG | CVnCoV | mRNA (encodes full-length spike protein of SARS-CoV-2) | NCT04674189 | Germany |
| AstraZeneca/University of Oxford | ChAdOx1 nCoV-19/CoviShield | Viral vector (replication-deficient chimpanzee adenovirus vector the S protein of SARS-CoV-2) | NCT04400838 | United Kingdom |
| NCT04536051 | Brazil | |||
| ISRCTN89951424 | Brazil | |||
| CanSino Biologics | Ad5-nCoV | Viral vector (adenovirus type-5 (Ad5) vector containing the S protein of SARS-CoV-2) | NCT04526990 | Argentina, Chile, Mexico, Pakistan, Russia |
| NCT04540419 | Russia | |||
| Gamaleya Research Institute | Sputnik V (Gam-COVID-Vac) | Viral vector (recombinant adenovirus type 26 (rAd26) and recombinant adenovirus type 5 (rAd5) vectors the S protein of SARS-CoV-2) | NCT04564716 | Belarus |
| NCT04530396 | Russia | |||
| NCT04656613 | United Arab Emirates | |||
| NCT04642339 | Venezuela | |||
| NCT04640233 | India | |||
| Janssen Pharmaceutical Companies | Ad26.COV2.S | Viral vector (recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector the S protein of SARS-CoV-2) | NCT04614948 | United States of America, Belgium, France, Colombia, Germany, Philippines, South Africa, Spain, United Kingdom |
| NCT04505722 | United States of America, Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa |